Bioray Biotech Co., Ltd (7561) Stock Statistics & Valuation Metrics
Total Valuation
Bioray Biotech Co., Ltd has a market cap or net worth of TWD 481.36M. The enterprise value is ―.
- Market Cap
- TWD 481.36M
- Enterprise Value
- ―
Share Statistics
Bioray Biotech Co., Ltd has 30,085,262 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 30,085,262
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Bioray Biotech Co., Ltd’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 5.94%.
- Return on Equity (ROE)
- 0.07
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 5.94%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 2.82M
- Profits Per Employee
- 408.23K
- Employee Count
- 79
- Asset Turnover
- 0.42
- Inventory Turnover
- 2.13
Valuation Ratios
The current PE Ratio of Bioray Biotech Co., Ltd is 25.08. Bioray Biotech Co., Ltd’s PEG ratio is -0.68.
- PE Ratio
- 25.08
- PS Ratio
- 2.33
- PB Ratio
- 1.11
- Price to FCF
- 7.57
- Price to Operating Cash Flow
- 7.48
- PEG Ratio
- -0.68
Income Statement
In the last 12 months, Bioray Biotech Co., Ltd had revenue of 222.72M and earned 32.25M in profits. Earnings per share was 1.09.
- Revenue
- 222.72M
- Gross Profit
- 90.57M
- Operating Income
- 37.90M
- Pretax Income
- 41.24M
- Net Income
- 32.25M
- EBITDA
- 61.49M
- Earnings Per Share (EPS)
- 1.09
Cash Flow
In the last 12 months, operating cash flow was 63.95M and capital expenditures -225,000, giving a free cash flow of 63.72M billion.
- Operating Cash Flow
- 63.95M
- Free Cash Flow
- 63.72M
- Free Cash Flow per Share
- 2.17
Dividends & Yields
Bioray Biotech Co., Ltd pays an annual dividend of ―, resulting in a dividend yield of 5.94%
- Dividend Per Share
- ―
- Dividend Yield
- 5.94%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 13.21%
- Earnings Yield
- 4.01%
Stock Price Statistics
- Beta
- 0.15
- 52-Week Price Change
- -31.48%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 32.70
- Average Volume (3m)
- 21.23K
Financial Position
Bioray Biotech Co., Ltd as a current ratio of 7.85, with Debt / Equity ratio of 10.22%
- Current Ratio
- 7.85
- Quick Ratio
- 6.32
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -2.58
- Interest Coverage Ratio
- 58.66
Taxes
In the past 12 months, Bioray Biotech Co., Ltd has paid 8.99M in taxes.
- Income Tax
- 8.99M
- Effective Tax Rate
- 0.22
Enterprise Valuation
Bioray Biotech Co., Ltd EV to EBITDA ratio is 10.63, with an EV/FCF ratio of 6.97.
- EV to Sales
- 2.14
- EV to EBITDA
- 10.63
- EV to Free Cash Flow
- 6.97
- EV to Operating Cash Flow
- 6.94
Balance Sheet
Bioray Biotech Co., Ltd has TWD 109.21M in cash and marketable securities with TWD 70.98M in debt, giving a net cash position of TWD 38.23M billion.
- Cash & Marketable Securities
- TWD 109.21M
- Total Debt
- TWD 70.98M
- Net Cash
- TWD 38.23M
- Net Cash Per Share
- TWD 1.27
- Tangible Book Value Per Share
- TWD 14.67
Margins
Gross margin is 40.96%, with operating margin of 9.74%, and net profit margin of 9.26%.
- Gross Margin
- 40.96%
- Operating Margin
- 9.74%
- Pretax Margin
- 11.84%
- Net Profit Margin
- 9.26%
- EBITDA Margin
- 20.15%
- EBIT Margin
- 9.74%
Analyst Forecast
The average price target for Bioray Biotech Co., Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -9.95%
- EPS Growth Forecast
- -37.11%
